Internal Medicine, Medical Oncology · New York, NY
NPI
1427102490
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1190 5th Avenue
New York, NY, 10029
Phone (212) 241-6756
Groups this clinician bills Medicare through
Medicare paid, 2024
$31K
262 services
Medicare patients, 2024
82
Average age 72
Drug cost, 2024
$859K
156 prescriptions
Company payments, 2025
$92K
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Krzysztof J Misiukiewicz was code 99215 (office e&m - established), 211 times for 58 patients. In total Krzysztof J Misiukiewicz billed 262 services in 7 codes, and Medicare paid $31K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-08-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 211 | 58 | $117.16 | $25K |
| 99205 Office E&M - New | Facility | 15 | 15 | $150.66 | $2,260 |
By year: 2022 $40K for 310 services; 2023 $31K for 248 services; 2024 $31K for 262 services.
Medicare prescription drug claims, 2024
In 2024, the drug Krzysztof J Misiukiewicz prescribed most often to Medicare patients was Levothyroxine Sodium, with 42 prescriptions and refills. In total Krzysztof J Misiukiewicz wrote 156 Medicare prescriptions that cost $859K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 42 | 64 | 11 | $266 |
| Gavreto Pralsetinib | 24 | 24 | Under 11 | $387K |
| Ondansetron Odt Ondansetron | 17 | 17 | Under 11 | $166 |
| Lenvima Lenvatinib Mesylate | 13 | 13 | Under 11 | $324K |
| Pantoprazole Sodium Generic | 11 | 11 | Under 11 | $55.09 |
Brand drugs: 63 claims; generic drugs: 93 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Krzysztof J Misiukiewicz $92K ($92K in general payments such as food, travel and fees) from 14 companies. The largest payer was Merck Sharp & Dohme LLC with $60K.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 45 | $60K |
| Coherus Oncology, Inc. CHRS | 9 | $23K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 14 | $7,527 |
| Fennec Pharmaceuticals, Inc. FENC | 2 | $754 |
| GlaxoSmithKline, LLC. GSK | 9 | $186 |
| Regeneron Healthcare Solutions, Inc. REGN | 5 | $129 |
| Napo Pharmaceuticals Inc | 5 | $116 |
| Eisai Inc. 4523.T | 5 | $112 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $75.31 |
| Stemline Therapeutics Inc. | 3 | $72.65 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.